Ontario government will fast track,commercializations of pdcArkady Mandel, M.D., Ph.D., D.Sc. Interim Chief Executive Officer and Chief Scientific Officer of Theralase stated that, “Theralase is pleased to support world-class research aimed at optimizing our patented PDCs in a clinical setting. The peered-reviewed recognition of our technology, as well as the financial and technical support, from the Ontario government and world-class industry players, such as IBM and Altera (Intel) will fast-track the commercialization of Theralase’s PDC technology, which will ultimately directly benefit cancer patients. The ORF project will provide even greater insight and knowledge as to how our patented PDCs localize in tissue and how to optimize both the dose of the PDC and laser light to activate them to provide the highest safety and efficacy for individual patients stricken with this deadly disease. Scientific, medical, engineering, business and computational collaboration, combined with government support, will help not only the Company to commercialize our Anti-Cancer PDT technology, but also help to establish the use of PDT worldwide as an effective and impactful anti-cancer therapy. With so few treatments available and even fewer on the near-term horizon for various cancers, combined with an increase of cancer incidence, the medical community needs to fully embrace the cutting-edge technological advantages that have been developed by Theralase and now with the support of a world-class, multi-disciplinary team of esteemed researchers, scientists and clinicians. Through the ORF grant, the Company is leveraging resources to create value for both cancer patients and shareholders, while advancing our innovative technology through the various clinical stages with an end-game of commercialization. We strongly believe that our innovative PDCs and ground-breaking technologies, as well as the focus and strong work ethic of our teams, will support Theralase on our journey to commercial success." Comm